[EN] QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS<br/>[FR] COMPOSÉS CONTENANT DE LA QUINOXALINE EN TANT QU'INHIBITEURS DU VIRUS DE L'HÉPATITE C
申请人:ENANTA PHARM INC
公开号:WO2009064975A1
公开(公告)日:2009-05-22
The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Selective reduction of tertiary, allyl, and benzyl halides by zinc-modified cyanoborohydride in diethyl ether
作者:Sunggak Kim、Yong Jin Kim、Kyo Han Ahn
DOI:10.1016/s0040-4039(00)86272-3
日期:1983.1
Zinc-modified cyanoborohydride in diethyl ether reduces tertiary, allyl, and benzylhalides to the corresponding hydrocarbons but the reagent is inert toward primary alkyl, secondary alkyl, vinyl, and aryl halides.